GlassScriptPhysician profile
Brinda Singh
NPI 1437261831
$1,903.98
in general payments reported to CMS, 2019-2025
28 companies · $355 in 2025
The $355 reported for 2025 was more than what 83% of Pediatric Critical Care Medicine providers received nationally (typical 2025 total: $71.68).
See the full distribution for Pediatric Critical Care Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $103 · 2021: $194 · 2022: $128 · 2023: $329 · 2024: $599 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $297.24 | 2022-2024 | Jornay Pm |
| Corium, LLC | $267.31 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $152.70 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $150.61 | 2019-2024 | |
| Neos Therapeutics, LP | $98.27 | 2019-2025 | Adzenys Xr-Odt |
| Sanofi Pasteur INC. | $90.68 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $87.49 | 2023-2025 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $82.88 | 2020-2022 | |
| Glaxosmithkline, LLC. | $66.91 | 2020-2024 | Bexsero |
| Vertical Pharmaceuticals, LLC | $66.41 | 2024 | Relexxii |
| Cranial Technologies, INC | $64.43 | 2019-2025 | Doc Band |
| Seqirus USA INC | $64.35 | 2021-2025 | Flucelvax |
| Alk-Abello, INC | $52.27 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $41.36 | 2025 | Jornay Pm |
| Mylan Pharmaceuticals INC. | $40.77 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $40.21 | 2023-2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $32.55 | 2024 | |
| Azurity Pharmaceuticals, INC. | $31.81 | 2025 | Alvesco |
| Astrazeneca Pharmaceuticals LP | $28.51 | 2024 | Flumist Quadrivalent |
| Abbott Laboratories | $23.52 | 2025 | Id Now Instrument |
| Sobi, INC | $22.59 | 2021 | |
| Abbvie INC. | $18.69 | 2023 | Lo Loestrin Fe |
| Tris Pharma INC | $17.32 | 2021 | |
| Genentech USA, INC. | $15.17 | 2020 | |
| Mayne Pharma Commercial LLC | $13.81 | 2023 | |
| Adlon Therapeutics L.P. | $13.63 | 2020 | |
| Kaleo, INC. | $11.58 | 2019 | |
| Mission Pharmacal Company | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brinda Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.